Neurostimulation Devices Market Outlook 2031

  • The global neurostimulation devices market was valued at US$ 8.1 Bn in 2021
  • The global market is projected to grow at a CAGR of 10.8% from 2022 to 2031
  • The global neurostimulation devices market is anticipated to reach more than US$ 22 Bn by the end of 2031

Analysts’ Viewpoint on Neurostimulation Devices Market Scenario

The global neurostimulation devices market is anticipated to record double-digit growth during the forecast period due to the rise in prevalence of neurological disorders, increase in geriatric population, favorable reimbursement rates, and introduction of innovative technologies. Neurostimulation devices are increasingly used to treat various health conditions, such as the effects of stroke and even depression, among patients. Healthcare companies are investing in the development of tiny external controllers that can monitor any abnormal activity in the brain. Companies should plan to invest in the healthcare landscape of Asia Pacific, since the market in the region is projected to witness strong growth in the next few years.

neurostimulation devices market

Overview of Neurostimulation Devices Market

Neurostimulation devices are generally used to diagnose and treat disorders of autonomic nervous system (ANS), central nervous system (CNS), and peripheral nervous system (PNS). Demand for neurostimulators is rising, as these devices help in nociceptive pain management and neuropathic pain management. They also help in the management of epilepsy, depression, and Parkinson’s disease. Demand for neurostimulation devices declined during the COVID-19 pandemic, which has hampered market revenue. The market in Asia Pacific is likely to expand at the fastest growth rate during the forecast period, primarily due to the increase in incidence of neurological disorders such as arthritis and osteoporosis in countries such as Japan and China.

Request a sample to get extensive insights into the Neurostimulation Devices Market

Rise in Prevalence of Parkinson’s Disease to Drive Global Market

Parkinson’s disease is an age-related neurodegenerative disorder that affects large number of people across the world. It is characterized by muscle contraction, which leads to weakening of physical movement, tremors, muscle rigidity, and gait. It can affect multiple systems of the body.

According to the Parkinson’s Foundation, more than 10 million people live with Parkinson’s disease across the globe. Around one million people in the U.S. suffer from Parkinson's disease. Nearly 60,000 people in the U.S. are estimated to be diagnosed with Parkinson’s disease each year. The exact number of patients is not known primarily due to the incompleteness and inconsistencies of prevalence studies and underdiagnosed cases.

According to the Global Burden of Disease Study, about 13 million people across the globe are likely to be affected by Parkinson’s disease by 2040. China accounts for the largest number of patients with Parkinson’s disease in the world. Currently, around 2.5 million people in the country are afflicted with Parkinson’s disease. This number is expected to double by the end of 2030. Currently, 1.7% of population of China above the age of 65 is affected by Parkinson’s disease.

According to VIARTIS, Albania has the highest prevalence rate of Parkinson’s disease of 800 per 100,000 persons in the world. The highest incidence rate of Parkinson’s disease is observed in France, with around 36 to 49 cases per 100,000. According to the European Parkinson’s Disease Association, currently, around 1.2 million people in the European Union are afflicted with Parkinson’s disease. About 260,000 people in Germany, 150,000 in Italy, and 120,000 people in the U.K. suffer from Parkinson’s disease.

Technological Advancements and New Product Development to Boost Market

Increase in demand for improved product outcomes & efficiency have led to development of innovative products and technologies to address the unmet needs of patients as well as surgeons. In order to provide improved and alternative solutions to unmet medical needs in neurological disorders, companies have developed novel technologies and devices, such as neurostimulation equipment, to improve the overall quality of life of the affected patient population. In January 2019, Boston Scientific Corporation launched the Vercise Primary Cell and Vercise Gevia Deep Brain Stimulation system for the treatment of symptoms of Parkinson’s disease. In December 2018, Axonics Modulation Technological, Inc. filed the Premarket Approval Application (PMA) with the U.S. FDA for the rechargeable implantable sacral neurostimulation system. In January 2017, Abbott Laboratories launched the new Proclaim DRG neurostimulation system in Europe. The Proclaim DRG neurostimulation system is designed to deliver dorsal root ganglion (DRG) stimulation for patients suffering from chronic neuropathic pain. Abbott is the first and only company that offers DRG therapy and targeted relief for certain types of chronic pain. Thus, the key trend of development and commercialization of novel electrical stimulation devices is driving the global neurostimulation devices market.

Request a custom report on Neurostimulation Devices Market

Launch of New Products with Updated Technologies to Propel Spinal Cord Stimulators Segment

The spinal cord stimulators segment accounted for dominant share of the global market in 2021. The segment is projected to grow at a high CAGR from 2022 to 2031.

High prevalence of chronic pain caused due to various reasons such as failed back surgery syndrome, cancer, traumatic pain, and nerve injuries; launch of new products with updated technologies in spinal cord stimulation; and favorable medical reimbursement policies in developed countries are projected to drive the segment during the forecast period.

Rise in Prevalence of Chronic Pain due to Various Medical Conditions to Augment Chronic Pain Segment

In terms of application, the global market has been divided into chronic pain, movement disorders, hearing impairments, epilepsy, urinary incontinence, and others. The chronic pain segment held significant market share in 2021 due to the rise in prevalence of chronic pain owing to various medical conditions such as cancer, trauma injuries, surgical trauma, and nerve injuries.

According to the Centers for Disease Control and Prevention (CDC), more than 50 million people were suffering from chronic pain in the U.S. in 2020. Chronic pain is the major cause of long term disability in the U.S. According to the European Pain Federation, around 80 million adults in Europe are living with chronic pain.

Well-established Health Care Infrastructure and Favorable Reimbursement Policies to Drive Hospitals Segment

Hospitals is projected to be a highly lucrative segment of the global neurostimulation market during the forecast period. Well-established health care infrastructure, favorable medical reimbursement facilities for neurostimulation devices in developed countries, and high cost of implantable devices contributed to the prominent share of the hospitals segment in 2021.

Rise in the number of hospitals in developing countries and increase in implantable neurostimulation surgeries are likely to drive the segment during the forecast period.

Regional Outlook of Neurostimulation Devices Market

North America accounted for the largest market share of around 60% in terms of revenue in 2021. The region is projected to dominate the global market during the forecast period. The market in North America is anticipated to expand at a CAGR of 10.5% from 2022 to 2031.

Early adoption of technologically advanced products, new product launches, and increase in installation of transcranial magnetic stimulation systems in specialty clinics in the U.S. and Canada contributed to the region's dominant share in 2021.

In May 2019, Nevro Corp. launched the Senza Omnia Spinal Cord Stimulation (SCS) System in the U.S. Omnia is the first and the only spinal cord stimulation system designed to deliver its proprietary HF10 therapy along with all other available spinal cord stimulator frequencies.

Increase in geriatric population in the U.S., high prevalence of neurological disorders & chronic pain, and high per capita healthcare expenditure in North America are likely to drive the market in the region during the forecast period.

Europe is projected to be the second most lucrative market for neurostimulation devices. The region held 20.8% share of the global market in 2021. Europe’s market share is likely to rise marginally to reach 21.7% by the end of 2031. The market in the region is expected to grow at a CAGR of 11.3% during the forecast period.

Asia Pacific is projected to be the fastest growing market from 2022 to 2031. This can be ascribed to the shift in production bases of several global manufacturers to the region due to high unmet medical needs and untapped growth opportunities. Additionally, rapid economic development in emerging countries such as India and China; and increase in healthcare expenditure are projected to augment the market in Asia Pacific.

Analysis of Key Players in Neurostimulation Devices Market

The global neurostimulation devices market is consolidated. A small number of players account for major share of the global market. Key players operating in the global neurostimulation devices market include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Nevro Corp., LivaNova plc, Axonics Modulation Technologies, Inc., Neuropace, Inc., EndoStim, Inc., NDI Medical, Cochlear Limited, and Neuronetics, Inc. These players have adopted various strategies such as product portfolio expansion, investment in research & development, development of novel neurostimulation devices, and mergers & acquisitions to establish a strong distribution network.

Key Developments in Neurostimulation Devices Market

  • In June 2021, Oticon Medical, one of the key players in the market, announced that the U.S. Food and Drug Administration (USFDA) granted and provided premarket approval to its Neuro System to treat and cure individuals 18 years or above. The system had been intended for the treatment of patients with bilateral severe-to-profound sensorineural hearing loss. This system is known as Neuro Cochlear Implant System.
  • In February 2019, Medtronic plc launched deep brain stimulation device for medically refractory epilepsy patients in the U.S.
  • In January 2018, LivaNova acquired ImThera Medical, Inc., a privately held medical device company. ImThera is engaged in the development of implantable neurostimulation device for the treatment of obstructive sleep apnea.

Each of these players has been profiled in the neurostimulation devices market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Neurostimulation Devices Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 8.1 Bn

Market Forecast Value in 2031

US$ 22.3 Bn

Growth Rate (CAGR)

10.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value & Units for Volume

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market Share Analysis by Company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Spinal Cord Stimulators
    • Deep Brain Stimulators
    • Cochlear Implants
    • Vagus Nerve Stimulators
    • Sacral Nerve Stimulators
    • Percutaneous Tibial Nerve Stimulators
    • Transcranial Magnetic Stimulators
  • Application
    • Chronic Pain
    • Movement Disorders
    • Hearing Impairment
    • Epilepsy
    • Urinary Incontinence
    • Others
  • End-user
    • Hospitals
    • Ambulatory Surgery Centers
    • Specialty Clinics

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Abbott Laboratories
  • Boston Scientific Corporation
  • Bioinduction
  • Integer Holdings Corporation
  • Medtronic
  • Nevro Corporation
  • Neurosigma, Inc.
  • Neuropace, Inc.
  • Neuronetics
  • Synapse Biomedical
  • Soterix Medical

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

The global neurostimulation devices market was valued at US$ 8.1 Bn in 2021.

The global neurostimulation devices market is projected to reach more than US$ 22.3 Bn by 2031.

The global neurostimulation devices market expanded at a CAGR of 10.0% from 2017 to 2021.

The global neurostimulation devices market is anticipated to expand at a CAGR of 10.8% from 2022 to 2031.

Rise in prevalence of Parkinson’s disease drives the global neurostimulation devices market.

North America is expected to account for major share of the global neurostimulation devices market during the forecast period.

Prominent players in the global neurostimulation devices market include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Nevro Corp., LivaNova plc, Axonics Modulation Technologies, Inc., Neuropace, Inc., EndoStim, Inc., NDI Medical, Cochlear Limited, and Neuronetics, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neurostimulation Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Neurostimulation Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

    5.1. Technological Advancements

    5.2. Disease Prevalence & Incidence rate globally with key countries

    5.3. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.4. COVID-19 Impact on Industry

6. Global Neurostimulation Market Analysis and Forecast, by Product Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product Type, 2017–2031

        6.3.1. Spinal Cord Stimulators

        6.3.2. Deep Brain Stimulators

        6.3.3. Cochlear Implants

        6.3.4. Vagus Nerve Stimulators

        6.3.5. Sacral Nerve Stimulators

        6.3.6. Percutaneous Tibial Nerve Stimulators

        6.3.7. Transcranial Magnetic Stimulators

    6.4. Market Attractiveness Analysis, by Product Type

7. Global Neurostimulation Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2017–2031

        7.3.1. Hospitals

        7.3.2. Ambulatory Surgery Centers

        7.3.3. Specialty Clinics

    7.4. Market Attractiveness Analysis, by End-user

8. Global Neurostimulation Market Analysis and Forecast, by Application

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Application, 2017–2031

        8.3.1. Chronic Pain

        8.3.2. Movement Disorders

        8.3.3. Hearing Impairment

        8.3.4. Epilepsy

        8.3.5. Urinary Incontinence

        8.3.6. Others

    8.4. Market Attractiveness Analysis, by Application

9. Global Neurostimulation Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Neurostimulation Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Product Type, 2017–2031

        10.2.1. Spinal Cord Stimulators

        10.2.2. Deep Brain Stimulators

        10.2.3. Cochlear Implants

        10.2.4. Vagus Nerve Stimulators

        10.2.5. Sacral Nerve Stimulators

        10.2.6. Percutaneous Tibial Nerve Stimulators

        10.2.7. Transcranial Magnetic Stimulators

    10.3. Market Value Forecast, by End-user, 2017–2031

        10.3.1. Hospitals

        10.3.2. Ambulatory Surgery Centers

        10.3.3. Specialty Clinics

    10.4. Market Value Forecast, by Application, 2017–2031

        10.4.1. Chronic Pain

        10.4.2. Movement Disorders

        10.4.3. Hearing Impairment

        10.4.4. Epilepsy

        10.4.5. Urinary Incontinence

        10.4.6. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Product Type

        10.6.2. By End-user

        10.6.3. By Application

        10.6.4. By Country

11. Europe Neurostimulation Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product Type, 2017–2031

        11.2.1. Spinal Cord Stimulators

        11.2.2. Deep Brain Stimulators

        11.2.3. Cochlear Implants

        11.2.4. Vagus Nerve Stimulators

        11.2.5. Sacral Nerve Stimulators

        11.2.6. Percutaneous Tibial Nerve Stimulators

        11.2.7. Transcranial Magnetic Stimulators

    11.3. Market Value Forecast, by End-user, 2017–2031

        11.3.1. Hospitals

        11.3.2. Ambulatory Surgery Centers

        11.3.3. Specialty Clinics

    11.4. Market Value Forecast, by Application, 2017–2031

        11.4.1. Chronic Pain

        11.4.2. Movement Disorders

        11.4.3. Hearing Impairment

        11.4.4. Epilepsy

        11.4.5. Urinary Incontinence

        11.4.6. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Product Type

        11.6.2. By End-user

        11.6.3. By Application

        11.6.4. By Country/Sub-region

12. Asia Pacific Neurostimulation Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product Type, 2017–2031

        12.2.1. Spinal Cord Stimulators

        12.2.2. Deep Brain Stimulators

        12.2.3. Cochlear Implants

        12.2.4. Vagus Nerve Stimulators

        12.2.5. Sacral Nerve Stimulators

        12.2.6. Percutaneous Tibial Nerve Stimulators

        12.2.7. Transcranial Magnetic Stimulators

    12.3. Market Value Forecast, by End-user, 2017–2031

        12.3.1. Hospitals

        12.3.2. Ambulatory Surgery Centers

        12.3.3. Specialty Clinics

    12.4. Market Value Forecast, by Application, 2017–2031

        12.4.1. Chronic Pain

        12.4.2. Movement Disorders

        12.4.3. Hearing Impairment

        12.4.4. Epilepsy

        12.4.5. Urinary Incontinence

        12.4.6. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Product Type

        12.6.2. By End-user

        12.6.3. By Application

        12.6.4. By Country/Sub-region

13. Latin America Neurostimulation Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product Type, 2017–2031

        13.2.1. Spinal Cord Stimulators

        13.2.2. Deep Brain Stimulators

        13.2.3. Cochlear Implants

        13.2.4. Vagus Nerve Stimulators

        13.2.5. Sacral Nerve Stimulators

        13.2.6. Percutaneous Tibial Nerve Stimulators

        13.2.7. Transcranial Magnetic Stimulators

    13.3. Market Value Forecast, by End-user, 2017–2031

        13.3.1. Hospitals

        13.3.2. Ambulatory Surgery Centers

        13.3.3. Specialty Clinics

    13.4. Market Value Forecast, by Application, 2017–2031

        13.4.1. Chronic Pain

        13.4.2. Movement Disorders

        13.4.3. Hearing Impairment

        13.4.4. Epilepsy

        13.4.5. Urinary Incontinence

        13.4.6. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Product Type

        13.6.2. By End-user

        13.6.3. By Application

        13.6.4. By Country/Sub-region

14. Middle East & Africa Neurostimulation Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Product Type, 2017–2031

        14.2.1. Spinal Cord Stimulators

        14.2.2. Deep Brain Stimulators

        14.2.3. Cochlear Implants

        14.2.4. Vagus Nerve Stimulators

        14.2.5. Sacral Nerve Stimulators

        14.2.6. Percutaneous Tibial Nerve Stimulators

        14.2.7. Transcranial Magnetic Stimulators

    14.3. Market Value Forecast, by End-user, 2017–2031

        14.3.1. Hospitals

        14.3.2. Ambulatory Surgery Centers

        14.3.3. Specialty Clinics

    14.4. Market Value Forecast, by Application, 2017–2031

        14.4.1. Chronic Pain

        14.4.2. Movement Disorders

        14.4.3. Hearing Impairment

        14.4.4. Epilepsy

        14.4.5. Urinary Incontinence

        14.4.6. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Product Type

        14.6.2. By End-user  

        14.6.3. By Application

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. Abbott Laboratories

            15.3.1.1. Company Overview

            15.3.1.2. Financial Overview

            15.3.1.3. SWOT Analysis

            15.3.1.4. Strategic Overview

        15.3.2. Boston Scientific Corporation

            15.3.2.1. Company Overview

            15.3.2.2. Financial Overview

            15.3.2.3. SWOT Analysis

            15.3.2.4. Strategic Overview

        15.3.3. Bioinduction

            15.3.3.1. Company Overview

            15.3.3.2. Financial Overview

            15.3.3.3. SWOT Analysis

            15.3.3.4. Strategic Overview

        15.3.4. Integer Holdings Corporation

            15.3.4.1. Company Overview

            15.3.4.2. Financial Overview

            15.3.4.3. SWOT Analysis

            15.3.4.4. Strategic Overview

        15.3.5. Medtronic

            15.3.5.1. Company Overview

            15.3.5.2. Financial Overview

            15.3.5.3. SWOT Analysis

            15.3.5.4. Strategic Overview

        15.3.6. Nevro Corporation

            15.3.6.1. Company Overview

            15.3.6.2. Financial Overview

            15.3.6.3. SWOT Analysis

            15.3.6.4. Strategic Overview

        15.3.7. Neurosigma, Inc.

            15.3.7.1. Company Overview

            15.3.7.2. Financial Overview

            15.3.7.3. SWOT Analysis

            15.3.7.4. Strategic Overview

        15.3.8. Neuropace, Inc.

            15.3.8.1. Company Overview

            15.3.8.2. Financial Overview

            15.3.8.3. SWOT Analysis

            15.3.8.4. Strategic Overview

        15.3.9. Neuronetics

            15.3.9.1. Company Overview

            15.3.9.2. Financial Overview

            15.3.9.3. SWOT Analysis

            15.3.9.4. Strategic Overview

        15.3.10. Synapse Biomedical

            15.3.10.1. Company Overview

            15.3.10.2. Financial Overview

            15.3.10.3. SWOT Analysis

            15.3.10.4. Strategic Overview

        15.3.11. Soterix Medical

            15.3.11.1. Company Overview

            15.3.11.2. Financial Overview

            15.3.11.3. SWOT Analysis

            15.3.11.4. Strategic Overvie

        15.3.12. Other Players

List of Tables

Table 01: Global Neurostimulation Devices Market Size (US$ Bn) Forecast, by Product, 2017–2031

Table 02: Global Neurostimulation Devices Market Volume (Units) Forecast, by Product, 2017–2031

Table 03: Global Neurostimulation Devices Market Size (US$ Bn) Forecast, by Application, 2017–2031

Table 04: Global Neurostimulation Devices Market Size (US$ Bn) Forecast, by End-user, 2017–2031

Table 05: Global Neurostimulation Devices Market Size (US$ Bn) Forecast, by Region, 2017–2031

Table 06: North America Neurostimulation Devices Market Size (US$ Bn) Forecast, by Country, 2017–2031

Table 07: North America Neurostimulation Devices Market Size (US$ Bn) Forecast, by Product, 2017–2031

Table 08: North America Neurostimulation Devices Market Volume (Units) Forecast, by Product, 2017–2031

Table 09: North America Neurostimulation Devices Market Size (US$ Bn) Forecast, by Application, 2017–2031

Table 10: North America Neurostimulation Devices Market Size (US$ Bn) Forecast, by End-user, 2017–2031

Table 11: Europe Neurostimulation Devices Market Revenue (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Neurostimulation Devices Market Size (US$ Bn) Forecast, by Product, 2017–2031

Table 13: Europe Neurostimulation Devices Market Volume (Units) Forecast, by Product, 2017–2031

Table 14: Europe Neurostimulation Devices Market Size (US$ Bn) Forecast, by Application, 2017–2031

Table 15: Europe Neurostimulation Devices Market Size (US$ Bn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Neurostimulation Devices Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Asia Pacific Neurostimulation Devices Market Size (US$ Bn) Forecast, by Product, 2017–2031

Table 18: Asia Pacific Neurostimulation Devices Market Volume (Units) Forecast, by Product, 2017–2031

Table 19: Asia Pacific Neurostimulation Devices Market Size (US$ Bn) Forecast, by Application, 2017–2031

Table 20: Asia Pacific Neurostimulation Devices Market Size (US$ Bn) Forecast, by End-user, 2017–2031

Table 21: Latin America Neurostimulation Devices Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Latin America Neurostimulation Devices Market Size (US$ Bn) Forecast, by Product, 2017–2031

Table 23: Latin America Neurostimulation Devices Market Volume (Units) Forecast, by Product, 2017–2031

Table 24: Latin America Neurostimulation Devices Market Size (US$ Bn) Forecast, by Application, 2017–2031

Table 25: Latin America Neurostimulation Devices Market Size (US$ Bn) Forecast, by End-user, 2017–2031

Table 26: Middle East & Africa Neurostimulation Devices Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Middle East & Africa Neurostimulation Devices Market Size (US$ Bn) Forecast, by Product, 2017–2031

Table 28: Middle East & Africa Neurostimulation Devices Market Volume (Units) Forecast, by Product, 2017–2031

Table 29: Middle East & Africa Neurostimulation Devices Market Size (US$ Bn) Forecast, by Application, 2017–2031

Table 30: Middle East & Africa Neurostimulation Devices Market Size (US$ Bn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Neurostimulation Devices Market Size (US$ Bn) Forecast, 2017–2031

Figure 02: Global Neurostimulation Devices Market Volume (Units) Forecast, 2017–2031

Figure 03: Market Value Share, by Product, 2021

Figure 04: Market Value Share, by Application, 2021

Figure 05: Market Value Share, by End-user, 2021

Figure 06: Market Value Share, by Region, 2021

Figure 07: Global Neurostimulation Devices Market Value Share Analysis, by Product, 2021 and 2031

Figure 08: Global Neurostimulation Devices Market Attractiveness Analysis, by Product, 2022–2031

Figure 09: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Spinal Cord Stimulators, 2017–2031

Figure 10: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Deep Brain Stimulators, 2017–2031

Figure 11: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Cochlear Implants, 2017–2031

Figure 12: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Vagus Nerve Stimulators, 2017–2031

Figure 13: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Sacral Nerve Stimulators, 2017–2031

Figure 14: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Percutaneous Tibial Nerve Stimulators, 2017–2031

Figure 15: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Transcranial Magnetic Stimulation, 2017–2031

Figure 16: Global Neurostimulation Devices Market Value Share Analysis, by Application, 2021 and 2031

Figure 17: Global Neurostimulation Devices Market Attractiveness Analysis, by Application, 2022–2031

Figure 18: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Chronic Pain, 2017–2031

Figure 19: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Movement Disorders, 2017–2031

Figure 20: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Hearing Impairment, 2017–2031

Figure 21: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Epilepsy, 2017–2031

Figure 22: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Urinary Incontinence, 2017–2031

Figure 23: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Major Depressive Disorders, 2017–2031

Figure 24: Global Neurostimulation Devices Market Value Share Analysis, by End-user, 2021 and 2031

Figure 25: Global Neurostimulation Devices Market Attractiveness Analysis, by End-user, 2022–2031

Figure 26: Global Neurostimulation Devices Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Hospitals, 2017–2031

Figure 27: Global Neurostimulation Devices Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Ambulatory Surgery Centers, 2017–2031

Figure 28: Global Neurostimulation Devices Revenue (US$ Bn) Forecast and Y-o-Y Growth (%), by Specialty Clinics, 2017–2031

Figure 29: Global Neurostimulation Devices Market Value Share, by Region, 2021 and 2031 

Figure 30: Global Neurostimulation Devices Market Attractiveness Analysis, by Region, 2022–2031

Figure 31: North America Neurostimulation Devices Market Size (US$ Bn) and Volume (Units) Forecast, 2017–2031

Figure 32: North America Neurostimulation Devices Market Value Share Analysis, by Country, 2021 and 2031

Figure 33: North America Neurostimulation Devices Market Attractiveness Analysis, by Country, 2022–2031

Figure 34: North America Neurostimulation Devices Market Value Share Analysis, by Product, 2021 and 2031

Figure 35: North America Neurostimulation Devices Market Attractiveness Analysis, by Product, 2019 -2031

Figure 36: North America Neurostimulation Devices Market Value Share Analysis, by Application, 2021 and 2031

Figure 37: North America Neurostimulation Devices Market Attractiveness Analysis, by Application, 2022–2031

Figure 38: North America Neurostimulation Devices Market Value Share Analysis, by End-user, 2021 and 2031

Figure 39: North America Neurostimulation Devices Market Attractiveness Analysis, by End-user, 2022–2031

Figure 40: Europe Neurostimulation Devices Market Size (US$ Bn) and Volume (Units) Forecast, 2017–2031

Figure 41: Europe Neurostimulation Devices Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 42: Europe Neurostimulation Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 43: Europe Neurostimulation Devices Market Value Share Analysis, by Product, 2021 and 2031

Figure 44: Europe Neurostimulation Devices Market Attractiveness Analysis, by Product, 2019 -2031

Figure 45: Europe Neurostimulation Devices Market Value Share Analysis, by Application, 2021 and 2031

Figure 46: Europe Neurostimulation Devices Market Attractiveness Analysis, by Application, 2022–2031

Figure 47: Europe Neurostimulation Devices Market Value Share Analysis, by End-user, 2021 and 2031

Figure 48: Europe Neurostimulation Devices Market Attractiveness Analysis, by End-user, 2022–2031

Figure 49: Asia Pacific Neurostimulation Devices Market Size (US$ Bn) and Volume (Units) Forecast, 2017–2031

Figure 50: Asia Pacific Neurostimulation Devices Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 51: Asia Pacific Neurostimulation Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 52: Asia Pacific Neurostimulation Devices Market Value Share Analysis, by Product, 2021 and 2031

Figure 53: Asia Pacific Neurostimulation Devices Market Attractiveness Analysis, by Product, 2022–2031

Figure 54: Asia Pacific Neurostimulation Devices Market Value Share Analysis, by Application, 2021 and 2031

Figure 55: Asia Pacific Neurostimulation Devices Market Attractiveness Analysis, by Application, 2022–2031

Figure 56: Asia Pacific Neurostimulation Devices Market Value Share Analysis, by End-user, 2021 and 2031

Figure 57: Asia Pacific Neurostimulation Devices Market Attractiveness Analysis, by End-user, 2022–2031

Figure 58: Latin America Neurostimulation Devices Market Size (US$ Bn) and Volume (Units) Forecast, 2017–2031

Figure 59: Latin America Neurostimulation Devices Market Value Share, by Country/Sub-region, 2021 and 2031

Figure 60: Latin America Neurostimulation Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 61: Latin America Neurostimulation Devices Market Value Share Analysis, by Product, 2021 and 2031

Figure 62: Latin America Neurostimulation Devices Market Attractiveness Analysis, by Product, 2022–2031

Figure 63: Latin America Neurostimulation Devices Market Value Share Analysis, by Application, 2021 and 2031

Figure 64: Latin America Neurostimulation Devices Market Attractiveness Analysis, by Application, 2022–2031

Figure 65: Latin America Neurostimulation Devices Market Value Share Analysis, by End-user, 2021 and 2031

Figure 66: Latin America Neurostimulation Devices Market Attractiveness Analysis, by End-user, 2022–2031

Figure 67: Middle East & Africa Neurostimulation Devices Market Size (US$ Bn) and Volume (Units) Forecast, 2017–2031

Figure 68: Middle East & Africa Neurostimulation Devices Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 69: Middle East & Africa Neurostimulation Devices Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 70: Latin America Neurostimulation Devices Market Value Share Analysis, by Product, 2021 and 2031

Figure 71: Latin America Neurostimulation Devices Market Attractiveness Analysis, by Product, 2022–2031

Figure 72: Middle East & Africa Neurostimulation Devices Market Value Share Analysis, by Application, 2021 and 2031

Figure 73: Middle East & Africa Neurostimulation Devices Market Attractiveness Analysis, by Application, 2022–2031

Figure 74: Middle East & Africa Neurostimulation Devices Market Value Share Analysis, by End-user, 2021 and 2031

Figure 75: Middle East & Africa Neurostimulation Devices Market Attractiveness Analysis, by End-user, 2022–2031

Figure 76: Global Neurostimulation Devices Market Share Analysis, by Company, 2021

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Neurostimulation Devices Market